Enediynes

Anticancer Agents from Natural Products

Volumn , Issue , 2005, Pages 451-474

  Hamann, Philip R ^a   Upeslacis, Janis ^a   Borders, Donald B ^b  

^a WYETH RESEARCH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; DISEASES; MONOCLONAL ANTIBODIES; ORGANIC COMPOUNDS;

ACUTE MYELOID LEUKEMIA; ANTI-TUMOR ACTIVITIES; ANTITUMOR ANTIBIOTICS; CALICHEAMICIN; CHEMICAL COMPLEXITY; CLINICAL TRIAL; NATURAL PRODUCTS; POLYMER BASED;

ANTIBIOTICS;

EID: 84886166673     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (217)

1. Enediyne Antibiotics as Antitumor Agents, Borders, D.B. and Doyle, T.W., Eds., Marcel Dekker, New York, 1995.
2. Lee, M.D., Ellestad, G.A., and Borders, D.B., Calicheamicins: Discovery, structure, chemistry, and interaction with DNA, Acc. Chem. Res., 24, 235, 1991.
3. Nicolaou, K.C. and Dai, W.M., Chemistry and biology of the enediyne anticancer antibiotics, Angew. Chem., Int. Ed. Engl., 30, 1387, 1991.
4. Smith, A.L. and Nicolaou, K.C., The enediyne antibiotics, J. Med. Chem., 39, 2103, 1996.
5. Nicolaou, K.C., Sorensen, E.J., and Winssinger, N., The art and science of organic and natural products synthesis, J. Chem. Educ., 75, 1225, 1998.
6. Xi, Z. and Goldberg, I.H., DNA-damaging enediyne compounds, in Comprehensive Natural Products Chemistry, Barton, D.S., Nakanishi, K., and Meth-Cohn, O., Eds., Pergamon Press, Oxford, UK, 1999, 7, 553.
7. Jones, G.B. and Fouad, F.S., Designed enediyne antitumor agents, Curr. Pharmaceut. Design, 8, 2415, 2002.
8. Shen, B., Liu, W., and Nonaka, K., Enediyne natural products: Biosynthesis and prospect towards engineering novel antitumor agents, Curr. Med. Chem., 10, 2317, 2003.
9. Neocarzinostatin: The Past, Present and Future of an Anticancer Drug, Maeda, H., Edo, K., and Ishida, N., Eds., Springer, New York, 1997.
10. Golik, J. et al., Esperamicins, a novel class of potent antitumor antibiotics. 2. Structure of esperamicin X., J. Am. Chem. Soc., 109, 3461, 1987.
11. Golik, J. et al., Esperamicins, a novel class of potent antitumor antibiotics. 3. Structures of esperamicins A1, A2, and A1b, J. Am. Chem. Soc., 109, 3462, 1987.
12. I, J. Am. Chem. Soc., 109, 3464, 1987.
13. I, J. Am. Chem. Soc., 109, 3466, 1987.
14. I: An antitumor antibiotic that cleaves double-stranded DNA site specifically, Science, 240, 1198, 1988.
15. I, J. Am. Chem. Soc., 114, 985, 1992.
16. Golik, J.A. et al., Antitumor Antibiotics, U.S. patent 5,086,045, 1992.
17. White, R.J., Maiese, W.M., and Greenstein, M., in Manual of Industrial Microbiology and Biotechnology, Demain, A.L. and Solomon, N.A., Eds., American Society of Microbiology, Washington, DC, 1986, 24.
18. I, J. Antibiot., 42, 1070, 1989.
19. Maiese, W.M. et al., Calicheamicins, a novel family of antitumor antibiotics: Taxonomy, fermentation and biological properties, J. Antibiot., 42, 558, 1989.
20. Edo, K. et al., The structure of neocarzinostatin chromophore possessing a novel bicyclo-7.3.0-dodecadiyne system, Tetrahedron Lett., 26, 331, 1985.
21. Lam, K.S. and Forenza, S., Fermentation and isolation of esperamicins, in Enediyne Antibiotics as Antitumor Agents, Borders, D.B. and Doyle, T.W., Eds., Marcel Dekker, New York, 1995, chap. 10.
22. Ando, T. et al., A new non-protein enediyne antibiotic N1999A2: Unique enediyne chromophore similar to neocarzinostatin and DNA cleavage feature, Tetrahedron Lett., 39, 6495, 1998.
23. Takashima, H., Amiya, S., and Kobayashi, Y., Neocarzinostatin: Interaction between the antitumoractive chromophore and the carrier protein, J. Biochem., 109, 807, 1991.
24. Hofstead, S.J. et al., Kedarcidin, a new chromoprotein antitumor antibiotic. II. Isolation, purification and physico-chemical properties, J. Antibiot., 45, 1250, 1992.
25. Kim, K.H. et al., Crystal structure of neocarzinostatin, an antitumor protein-chromophore complex, Science, 262, 1042, 1993.
26. Okuno, Y., Otsuka, M., and Sugiura, Y., Computer modeling analysis for enediyne chromophoreapoprotein complex of macromolecular antitumor antibiotic C-1027, J. Med. Chem., 37, 2266, 1994.
27. Teplyakov, A. et al., Crystal structure of apo-neocarzinostatin at 0.15-nm resolution, Eur. J. Biochem., 213, 737, 1993.
28. Chin, D.H., Rejection by neocarzinostatin protein through charges rather than sizes, Chem.-Eur. J., 5, 1084, 1999.
29. Usuki, T. et al., Rational design of supra C-1027: Kinetically stabilized analog of the antitumor enediyne chromoprotein, J. Am. Chem. Soc., 126, 3022, 2004.
30. Zein, N. et al., Selective proteolytic activity of the antitumor agent kedarcidin, Proc. Natl. Acad. Sci. U.S.A., 90, 8009, 1993.
31. Sakata, N. et al., Aminopeptidase activity of an antitumor antibiotic, C-1027, J. Antibiot., 45, 113, 1992.
32. I: 3. The final stages, J. Am. Chem. Soc., 115, 7625, 1993.
33. I, Angew. Chem., Int. Ed. Engl., 33, 858, 1994.
34. I, J. Am. Chem. Soc., 114, 10082, 1992.
35. Leet, J.E. et al., Kedarcidin, a new chromoprotein antitumor antibiotic: Structure elucidation of kedarcidin chromophore, J. Am. Chem. Soc., 114, 7946, 1992.
36. Leet, J.E. et al., Kedarcidin chromophore: Structure elucidation of the amino sugar kedarosamine, Tetrahedron Lett., 33, 6107, 1992.
37. Kawata, S. and Hirama, M., Synthetic study of the kedarcidin chromophore: Efficient construction of the aryl alkyl ether linkage, Tetrahedron Lett., 39, 8707, 1998.
38. Myers, A.G. et al., Total synthesis of (+)-neocarzinostatin chromophore, J. Am. Chem. Soc., 120, 5319, 1998.
39. Kobayashi, S. et al., The first total synthesis of N1999-A2: Absolute stereochemistry and stereochemical implications into DNA cleavage, J. Am. Chem. Soc., 123, 11294, 2001.
40. Kobayashi, S. et al., Investigation of the total synthesis of N1999-A2: Implication of stereochemistry, J. Am. Chem. Soc., 123, 2887, 2001.
41. Konishi, M. et al., Crystal and molecular structure of dynemicin A: A novel 1,5-diyn-3-ene antitumor antibiotic, J. Am. Chem. Soc., 112, 3715, 1990.
42. Myers, A.G. et al., A convergent synthetic route to (+)-dynemicin A and analogs of wide structural variability, J. Am. Chem. Soc., 119, 6072, 1997.
43. Shair, M.D. et al., The total synthesis of dynemicin A leading to development of a fully contained bioreductively activated enediyne prodrug, J. Am. Chem. Soc., 118, 9509, 1996.
44. Yoshida, K.-I. et al., Structure and cycloaromatization of a novel enediyne, C-1027 chromophore, Tetrahedron Lett., 34, 2637, 1993.
45. Iida, K.-I. et al., Synthesis and absolute stereochemistry of the aminosugar moiety of antibiotic C-1027 chromophore, Tetrahedron Lett., 34, 4079, 1993.
46. Schroeder, D.R. et al., Isolation, structure determination and proposed mechanism of action for artifacts of maduropeptin chromophore, J. Am. Chem. Soc., 116, 9351, 1994.
47. McDonald, L.A. et al., Namenamicin, a new enediyne antitumor antibiotic from the marine ascidian Polysyncraton lithostrotum, J. Am. Chem. Soc., 118, 10898, 1996.
48. Oku, N., Matsunaga, S., and Fusetani, N., Shishijimicins A-C, novel enediyne antitumor antibiotics from the ascidian Didemnum proliferum, J. Am. Chem. Soc., 125, 2044, 2003.
49. Samy, T.S. et al., Primary structure of macromomycin, an antitumor antibiotic protein, J. Biol. Chem., 258, 183, 1983.
50. Suzuki, H. et al., Biological activities of non-protein chromophores of antitumor protein antibiotics: Auromomycin and neocarzinostatin, Biochem. Biophys. Res. Commun., 94, 255, 1980.
51. Doyle, T.W. and Borders, D.B., Enediyne antitumor antibiotics, in Enediyne Antibiotics as Antitumor Agents, Borders, D.B. and Doyle, T.W., Eds., Marcel Dekker, New York, 1995, chap. 1.
52. Fantini, A.A. and Testa, R.T., Taxonomy, fermentation and yield improvement, in Enediyne Antibiotics as Antitumor Agents, Borders, D.B. and Doyle, T.W., Eds., Marcel Dekker, New York, 1995, chap. 3.
53. Hensens, O.D., Giner, J.-L., and Goldberg, I.H., Biosynthesis of NCS Chrom A, the chromophore of the antitumor antibiotic neocarzinostatin, J. Am. Chem. Soc., 111, 3295, 1989.
54. Lam, K.S. et al., Biosynthesis of esperamicin A1, an enediyne antitumor antibiotic, J. Am. Chem. Soc., 115, 12340, 1993.
55. Lam, K.S. et al., Inhibition of esperamicin A1 synthesis by cerulenin, Abstr. Annu. Meet. Am. Soc. Microbiol., 90, 266, 1990.
56. Tokiwa, Y. et al., Biosynthesis of dynemicin A, a 3-ene-1,5-diyne antitumor antibiotic, J. Am. Chem. Soc., 114, 4107, 1992.
57. Ahlert, J. et al., The calicheamicin gene cluster and its iterative type I enediyne PKS, Science, 297, 1173, 2002.
58. Liu, W. et al., Biosynthesis of the enediyne antitumor antibiotic C-1027, Science, 297, 1170, 2002.
59. Wen, L. et al., Rapid PCR amplification of minimal enediyne polyketide synthase cassettes leads to a predictive familial classification model, Proc. Natl. Acad. Sci. U. S. A., 100, 11959, 2003.
60. Thorson, J.S. et al., Understanding and exploiting nature’s chemical arsenal: The past, present and future of calicheamicin research, Curr. Pharmaceut. Design, 6, 1841, 2000.
61. Christenson, S.D. et al., A novel 4-methylideneimidazole-5-one-containing tyrosine aminomutase in enediyne antitumor antibiotic C-1027 biosynthesis, J. Am. Chem. Soc., 125, 6062, 2003.
62. Liu, W. and Shen, B., Genes for production of the enediyne antitumor antibiotic C-1027 in Streptomyces lobisporus are clustered with the cagA gene that encodes the C-1027 apoprotein, Antimicrob. Agents Chemother., 44, 382, 2000.
63. Biggins, J.B., Onwueme, K., and Thorson, J.S., Resistance to enediyne antitumor antibiotics by CalC self-sacrifice, Science, 301, 1537, 2003.
64. Kudo, K. et al., Production of a free chromophore component of neocarzinostatin (NCS) in the culture filtrate of Streptomyces carzinostaticus var. F-41, J. Antibiot., 35, 1111, 1982.
65. Bergman, R.G., Reactive 1,4-dehydroaromatics, Acc. Chem. Res., 6, 25, 1973.
66. Chen, W.C., Chang, N.Y., and Yu, C.H., Density functional study of Bergman cyclization of enediynes, J. Phys. Chem. A, 102, 2584, 1998.
67. Schreiner, P.R., Cyclic enediynes — relationship between ring size, alkyne carbon distance, and cyclization barrier, Chem. Comm., 483, 1998.
68. Biswas, K. et al., The molecular basis for pyrimidine-selective DNA binding: Analysis of calicheamicin oligosaccharide derivatives by capillary electrophoresis, J. Am. Chem. Soc., 122, 8413, 2000.
69. Walker, S.L., Andreotti, A.H., and Kahne, D.E., NMR characterization of calicheamicin bound to DNA, Tetrahedron, 50, 1351, 1994.
70. Walker, S. et al., Analysis of hydroxylamine glycosidic linkages: Structural consequences of the NO bond in calicheamicin, J. Am. Chem. Soc., 116, 3197, 1994.
71. Paloma, L.G. et al., Interaction of calicheamicin with duplex DNA: Role of the oligosaccharide domain and identification of multiple binding modes, J. Am. Chem. Soc., 116, 3697, 1994.
72. Ikemoto, N. et al., Calicheamicin-DNA complexes: Warhead alignment and saccharide recognition of the minor groove, Proc. Natl. Acad. Sci. U.S.A., 92, 10506, 1995.
73. Miyagawa, N. et al., DNA cleavage characteristics of non-protein enediyne antibiotic N1999-2A, Biochem. Biophys. Res. Commun., 306, 87, 2003.
74. De Voss, J.J., Hangeland, J.J., and Townsend, C.A., Characterization of the in-vitro cyclization chemistry of calicheamicin and its relation to DNA cleavage, J. Am. Chem. Soc., 112, 4554, 1990.
75. I, J. Am. Chem. Soc., 111, 6888, 1989.
76. I complex, J. Am. Chem. Soc., 112, 9669, 1990.
77. Kumar, R.A., Ikemoto, N., and Patel, D.J., Solution structure of the calicheamicin γ1 I-DNA complex, J. Mol. Biol., 265, 187, 1997.
78. Sugiura, Y. et al., Reductive and nucleophilic activation products of dynemicin A with methyl thioglycolate. A rational mechanism for DNA cleavage of the thiol-activated dynemicin A, Biochemistry, 30, 2989, 1991.
79. Nicolaou, K.C. et al., Molecular design, chemical synthesis, kinetic studies, calculations, and biological studies of novel enediynes equipped with triggering, detection, and deactivating devices: Model dynemicin A epoxide and cis-diol systems, J. Am. Chem. Soc., 115, 7944, 1993.
80. Cosgrove, J.P., and Dedon, P.C., Binding and reaction of calicheamicin and other enediyne antibiotics with DNA, in Small Molecule DNA and RNA Binders, Demeunynck, M., Bailly, C., and Wilson, W.D., Eds., Wiley-VCH, Weinheim, Germany, 2003, 2, 609.
81. Xu, Y.-J., Zhen, Y.-S., and Goldberg, I.H., C1027 chromophore, a potent new enediyne antitumor antibiotics, induces sequence-specific double-strand DNA cleavage, Biochemistry, 33, 5947, 1994.
82. Xu, Y.J., Zhen, Y.S., and Goldberg, I.H., Enediyne C1027 induces the formation of novel covalent DNA interstrand cross-links and monoadducts, J. Am. Chem. Soc., 119, 1133, 1997.
83. Cobuzzi, R.J., Jr. et al., Effects of the enediyne C-1027 on intracellular DNA targets, Biochemistry, 34, 583, 1995.
84. I, DNA Repair, 2, 363, 2003.
85. Susanne, M. et al., Activation of the DNA-dependent protein kinase by drug-induced and radiationinduced DNA strand breaks, Radiation Research, 160, 291, 2003.
86. Jiang, B., Li, D.D., and Zhen, Y.S., Induction of apoptosis by enediyne antitumor antibiotic C1027 in HL-60 human promyelocytic leukemia cells, Biochem. Biophys. Res. Commun., 208, 238, 1995.
87. He, Q. and Li, D., Interaction of direct breaking DNA strands and initiating of apoptotic pathway contributed to high potent cytotoxicities of enediyne antibiotic lidamycin (C1027) to human tumor cells, Proc. Am. Assoc. Cancer Res., 42, 643, 2001.
88. Wang, Z. et al., Non-caspase-mediated apoptosis contributes to the potent cytotoxicity of the enediyne antibiotic lidamycin toward human tumor cells, Biochem. Pharmacol., 65, 1767, 2003.
89. Dziegielewski, J. and Beerman, T.A., C-1027-induced activation of DNA-damage responses is ATMindependent, Proc. Am. Assoc. Cancer Res., 42, 199, 2001.
90. Amico, D. et al., Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: Role of Chk1 and Chk2 phosphorylation and caspase 3, Blood, 101, 4589, 2003.
91. McHugh, M.M. et al., The cellular response to DNA damage induced by the enediynes C-1027 and neocarzinostatin includes hyperphosphorylation and increased nuclear retention of replication protein A (RPA) and trans inhibition of DNA replication, Biochemistry, 40, 4792, 2001.
92. Hiatt, A. et al., Regulation of apoptosis in leukemic cells by analogs of dynemicin A, Bioorg. Med. Chem., 2, 315, 1994.
93. Hartsell, T.L. et al., Determinants of the response of neuroblastoma cells to DNA damage: The roles of pre-treatment cell morphology and chemical nature of the damage, J. Pharmacol. Exp. Ther., 277, 1158, 1996.
94. Liang, Y. et al., Early events in Bcl-2-enhanced apoptosis, Apoptosis, 8, 609, 2003.
95. 1: A rationally designed molecule with extremely potent and selective DNA cleaving properties and apoptosis inducing activity, Angew. Chem., Int. Ed. Engl., 33, 183, 1994.
96. Wrasidlo, W. et al., Modulation of p53 expression in neuroblastoma cell lines by the DNA cleaving agent calicheamicin theta, Proc. Am. Assoc. Cancer Res., 38, 610, 1997.
97. Prokop, A. et al., Induction of apoptosis by enediyne antibiotic calicheamicin θ proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner, Oncogene, 22, 9107, 2003.
98. Siegel, J. et al., Enhanced p53 activity and accumulation in response to DNA damage upon DNA transfection, Oncogene, 11, 1363, 1995.
99. Andreeff, M. et al., Caspase independent cell death in AML: An in vivo study in patients undergoing chemotherapy, Blood, 98, 208b, 2001.
100. Batchelder, R.M. et al., Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A-1, Br. J. Cancer, 74, S52, 1996.
101. Van Duijn-Goedhart, A. et al., Differential responses of Chinese hamster mutagen sensitive cell lines to low and high concentrations of calicheamicin and neocarzinostatin, Mutat. Res., 471, 95, 2000.
102. Noel, G. et al., Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery, BMC Cell Biology, http://www.biomedcentral.com/content/pdf/1471-2121-4-7.pdf, 2003.
103. Jedema, I. et al., Sensitivity of acute myeloid leukemia cells to anti-CD33-calicheamicin (gemtuzumab ozogamicin) is cell cycle-dependent and can be increased by interferon gamma, Blood, 98, 120a (abst. 503), 2001.
104. Cortazzo, M. and Schor, N.F., Potentiation of enediyne-induced apoptosis and differentiation by Bcl-2, Cancer Res., 56, 1199, 1996.
105. Kappen, L.S. and Goldberg, I.H., Activation and inactivation of neocarzinostatin-induced cleavage of DNA, Nucleic Acids Res., 5, 2959, 1978.
106. Schor, N.F. et al., The use of 6-mercaptodopamine to target neuroblastoma cells for enediyne-induced apoptosis and antineoplastic effect, Proc. Am. Assoc. Cancer Res., 35, 316, 1994.
107. Maier, M.E., Bosse, F., and Niestroj, A.J., Design and synthesis of dynemicin analogs, Eur. J. Org. Chem., 1, 1999.
108. Zhen, Y.S. et al., Lidamycin and its RGD-containing peptide conjugate inhibit angiogenesis and metastasis, Proc. Am. Assoc. Cancer Res., 41, 645 (abst. 4098), 2000.
109. Liu, X.Y. et al., Antitumor effects of novel immunoconjugates with downsized-molecule prepared by linking lidamycin to Fab′ and scFv antibody, Proc. Am. Assoc. Cancer Res., 41, 290 (abst. 1848), 2000.
110. Wang, F., Shang, B., and Zhen, Y., Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab′ fragment of monoclonal antibody directed against type IV collagenase, Sci. China, Ser. C Life Sci., 47, 66, 2004.
111. Feng-Qiang, W., Bo-Yang, S., and Yong-Su, Z., Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11, Acta Pharmaceutica Sinica, 38, 515, 2003.
112. Zhen, Y.S. et al., Conjugate of antibiotic C1027 and monoclonal antibody 3H11 shows potent antitumor effect against gastric cancer, Proc. Am. Assoc. Cancer Res., 35, 511 (abst. 3047), 1994.
113. Wrasidlo, W. et al., In vivo efficacy of novel synthetic enediynes, Acta Oncol., 34, 157, 1995.
114. Hay, M.P., Wilson, W.R., and Denny, W.A., A novel enediyne prodrug for antibody-directed enzyme prodrug therapy (ADEPT) using E. coli B nitroreductase, Bioorg. Med. Chem. Lett., 5, 2829, 1995.
115. Hay, M.P., Wilson, W.R., and Denny, W.A., Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT), Bioorg. Med. Chem. Lett., 9, 3417, 1999.
116. Xie, Y. et al., Enediyne-lexitropsin DNA-targeted anticancer agents. Physicochemical and cytotoxic properties in human neoplastic cells in vitro, and intracellular distribution, Anti-Cancer Drug Des., 12, 169, 1997.
117. Severin, S.E. et al., Targeted delivery of esperamicin A1 by using oncofetal protein alpha-fetoprotein, Eur. J. Cancer, 33, S89, 1997.
118. Severin, S.E. et al., Alpha-fetoprotein-mediated targeting of anti-cancer drugs to tumor cells in vitro, Biochem. Mol. Biol. Int., 37, 385, 1995.
119. Capson, T. and Ruffner, D., Preparation of calicheamicin-oligodeoxynucleotide conjugates for use as antisense therapeutics, Pharm. Res. (New York), 13, S153, 1996.
120. Durr, F.E. et al., Biological activities of calicheamicin, in Enediyne Antibiotics as Antitumor Agents, Borders, D.B. and Doyle, T.W., Eds., Marcel Dekker, 1995.
121. Ellestad, G.A. et al., Reactions of the trisulfide moiety in calicheamicin, Tetrahedron Lett., 30, 3033, 1989.
122. Hinman, L.M. et al., Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics, Cancer Res., 53, 3336, 1993.
123. Jeglum, K.A. et al., Antitumor effects of a calicheamicin immunoconjugate with anti-canine lymphoma monoclonal antibody 231, Proc. Am. Assoc. Cancer Res., 35, 506 (abstr. 3016), 1994.
124. Hinman, L.M. et al., Lysine-linked conjugates of calicheamicin γ1 I with a fully humanized antipolymorphic epithelial mucin antibody show potent antitumor effects in ovarian tumor xenografts, Proc. Am. Assoc. Cancer Res., 34, 479 (Abs 2860), 1993.
125. Hamann, P.R. et al., An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker, Bioconj. Chem., 13, 40, 2002.
126. Bross, P.F. et al., Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia, Clin. Cancer Res., 7, 1490, 2001.
127. Bross, P.F. et al., Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia (correction to previous reference), Clin. Cancer Res., 8, 300, 2002.
128. Hamann, P.R. et al., Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia, Bioconj. Chem., 13, 47, 2002.
129. Jedema, I. et al., Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: Rationale for efficacy in CD33-negative malignancies with endocytic capacity, Leukemia, 18, 316, 2004.
130. van der Velden, V.H.J., Berger, M.S., and Van Dongen, J.J.M., Mylotarg therapy in acute myeloid leukemia: Mechanism of action and implications for future treatment protocols, Haematol. Blood Transfusion, 41, 169, 2003.
131. DiJoseph, J.F. et al., Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies, Blood, 103, 1807, 2004.
132. Boghaert, E.R. et al., Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-Nacetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts, Clinical Cancer Research, 10, 4538, 2004.
133. 1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma, Cancer Res., 58, 2925, 1998.
134. Burchardt, C.A. et al., Cytotoxic effects of new immunoconjugates in different neuroblastoma celllines, J. Cancer Res. Clin. Oncol., 124, 137, 1998.
135. Bernt, K.M. et al., CD19 targeted calicheamicin theta is effective against high risk ALL, Blood, 96, 467a, 2000.
136. Knoll, K. et al., Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin γI 1, Cancer Res., 60, 6089, 2000.
137. Schmidt, C.S. et al., Chemoimmunoconjugates with the monoclonal antibody 138H11 for targeting the cytotoxic prodrug calicheamicin θ to renal cell carcinomas, Tumor Target., 4, 271, 1999.
138. Otsuji, E. et al., The effect of intravenous and intra-tumoural chemotherapy using a monoclonal antibody-drug conjugate in a xenograft model of pancreatic cancer, Eur. J. Surg. Oncol., 21, 61, 1995.
139. Okamoto, K. et al., Targeted chemotherapy in mice with peritoneally disseminated gastric cancer using monoclonal antibody-drug conjugate, Cancer Lett., 122, 231, 1998.
140. Kitamura, K. et al., The role of monoclonal antibody A7 as a drug modifier in cancer therapy, Cancer Immunol. Immunother., 36, 177, 1993.
141. Yamaguchi, T. et al., Production, binding and cytotoxicity of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate, Jpn. J. Cancer Res., 84, 1190, 1993.
142. Otsuji, E. et al., Antitumor effect of neocarzinostatin conjugated to human/mouse chimeric Fab fragments of the monoclonal antibody A7 on human pancreatic carcinoma, J. Surg. Oncol., 57, 230, 1994.
143. Yamaguchi, T. et al., In vivo efficacy of neocarzinostatin coupled with Fab human/mouse chimeric monoclonal antibody A7 against human colorectal cancer, Jpn. J. Cancer Res., 85, 167, 1994.
144. Otsuji, E. et al., Effects of neocarzinostatin-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts, Br. J. Cancer, 73, 1178, 1996.
145. Matsumura, H. et al., Increased effects of neocarzinostatin-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts, Cancer Biother. Radiopharm., 13, 60, 1998.
146. Otsuji, E. et al., Biodistribution of neocarzinostatin conjugated to chimeric Fab fragments of the monoclonal antibody A7 in nude mice bearing human pancreatic cancer xenografts, Jpn. J. Cancer Res., 85, 530, 1994.
147. Yamaguchi, T. et al., Production of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate and distribution in tumor bearing athymic mice, Proc. Controlled Release Soc., 22, 544, 1995.
148. Otsuji, E. et al., Applicability of monoclonal antibody Fab fragments as a carrier of neocarzinostatin in targeting chemotherapy, J. Surg. Oncol., 61, 149, 1996.
149. Otsuji, E. et al., Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin, Br. J. Cancer, 74, 597, 1996.
150. Otsuji, E. et al., Decreased renal accumulation of biotinylated chimeric monoclonal antibody-neocarzinostatin conjugate after administration of avidin, Jpn. J. Cancer Res., 88, 205, 1997.
151. Nakaki, M., Takikawa, H., and Yamanaka, M., Targeting immunotherapy using the avidin-biotin system for a human colon adenocarcinoma in vitro, J. Int. Med. Res., 25, 14, 1997.
152. Tsunoda, S. et al., Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: A novel drug carrier for cancer targeting therapy, Br. J. Cancer, 81, 1155, 1999.
153. Makimoto, H. et al., Tumor vascular targeting using a tumor-tissue endothelium-specific monoclonal antibody as an effective strategy for cancer chemotherapy, Biochem. Biophys. Res. Commun., 260, 346, 1999.
154. Wakai, Y. et al., Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES-23), Jpn. J. Cancer Res., 91, 1319, 2000.
155. Maibucher, A. et al., Neocarzinostatin immunoconjugates: In vitro evaluation of therapeutic potential, Pharm. Sci. Commun., 4, 253, 1994.
156. Schonlau, F. et al., Mechanism of free and conjugated neocarzinostatin activity: Studies on chromophore and protein uptake using a transferrin-neocarzinostatin conjugate, Z. Naturforsch., C: Biosci., 52, 245, 1997.
157. Brown, T. et al., A phase II trial of BMY-28175 in advanced pancreatic carcinoma, Proc. Am. Soc. Clin. Oncol., 13, 219, 1994.
158. Melink, T. et al., A phase I trial of BMY-28175 on a single dose schedule, Proc. Am. Soc. Clin. Oncol., 10, 120, 1991.
159. Sessa, C. et al., Phase I study of BMY-28175 (esperamicin A1) on a single intermittent schedule, Proc. Am. Soc. Clin. Oncol., 9, 66, 1990.
160. Van Hof, A.C. et al., Biodistribution of 111indium-labeled engineered human antibody CTM01 in ovarian cancer patients: Influence of protein dose, Cancer Res., 56, 5179, 1996.
161. Gillespie, A.M. et al., Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with epithelial ovarian cancer, Ann. Oncol., 11, 735, 2000.
162. Broadhead, T.J. et al., CMB-401 — a new agent for immunotherapy of epithelial ovarian cancer: Immune response and pharmacokinetics, Br. J. Cancer, 78, 44, 1998.
163. Chan, S.Y. et al., A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma, Cancer Immunol. Immunother., 52, 243, 2003.
164. Mallick, R., Sievers, E., and Berger, M., A decision analysis of expected cost savings with outpatient administration of gemtuzumab ozogamicin (MylotargTM, CMA-676) in patients in first relapse of acute myeloid leukemia (AML), Blood, 96, 439a, 2000.
165. Lang, K. et al., Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia, Am. J. Health-Syst. Pharm., 59, 941, 2002.
166. Rajvanshi, P. et al., Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy, Blood, 99, 2310, 2002.
167. Erba, H.P. et al., Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin, Blood, 100, 339a (abstr. 1313), 2002.
168. Erba, H. et al., Results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin, Proc. Am. Soc. Clin. Oncol., 21, 270a, 2002.
169. Kell, W.J. et al., A feasibility study of Mylotarg (gemtuzumab ozogamicin, GO) in combination with standard induced therapy in acute myeloid leukaemia (AML), Br. J. Haematol., 117, 19, 2002.
170. Stadtmauer, E.A., Trials with gemtuzumab ozogamicin (Mylotarg®) combined with chemotherapy regimens in acute myeloid leukemia, Clinical Lymphoma, 2, S24, 2002.
171. Sievers, E.L., Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg), Blood Cells, Molecules, & Diseases, 31, 7, 2003.
172. Naito, K. et al., Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on p-glycoprotein-expressing sublines, Leukemia, 14, 1436, 2000.
173. Linenberger, M.L. et al., Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin, Blood, 98, 988, 2001.
174. Matsui, H. et al., Reduced effect of gemtuzumab ozogamicin (CMA-676) on p-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers, Leukemia, 16, 813, 2002.
175. Walter, R.B. et al., Multidrug resistance protein (MRP) attenuates gemtuzumab ozogamicin (GO)-induced cytotoxicity in acute myeloid leukemia (AML), Blood, 100, 224b (abstr. 4415), 2002.
176. Jilani, I. et al., Differences in CD33 intensity between various myeloid neoplasms, Am. J. Clin. Pathol., 118, 560, 2002.
177. Jilani, I. et al., Quantitative differences in CD33 intensity between various myeloid neoplasms, Blood, 98, 586a (abstr. 2458), 2001.
178. Becker, M.W., Qian, D., and Clarke, M.F., CD33 is variably expressed on leukemic stem cells in acute myelogenous leukemia, Blood, 98, 587a (abstr. 2459), 2001.
179. Introna, M. et al., Differential response of acute myeloid leukaemia cells to gemtuzumab ozogamicin (Mylotarg®) in vitro. Role of Chk1 and 2 phosphorylation and caspase 3, Blood, 100, 319a (abstr. 1237), 2002.
180. Sievers, E. et al., Preliminary report of an ascending dose study of gemtuzumab ozogamicin (MylotargTM, CMA-676) in pediatric patients with acute myeloid leukemia, Blood, 96, 217b, 2000.
181. Zwaan, Ch. M. et al., Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: First clinical experiences and relation with cellular sensitivity to single agent calicheamicin, Leukemia, 17, 468, 2003.
182. Sievers, E. et al., Final report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematopoietic stem cell transplantation, Blood, 100, 89a (abstr. 327), 2002.
183. Cohen, A.D. et al., Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: Efficacy and incidence of hepatic veno-occlusive disease, Bone Marrow Transplant., 30, 23, 2002.
184. Sievers, E.L. et al., Gemtuzumab ozogamicin (Mylotarg) as a single agent to evaluate safety and determine maximum tolerated dose (MTD) in post hematopoietic stem cell transplant patients with relapsed, CD33+ acute myeloid leukemia (AML), Blood, 100, 336a (abstr. 1304), 2002.
185. Goldberg, S.L. et al., Gemtuzumab ozogamicin (Mylotarg) prior to allogeneic hematopoietic stem cell transplantation increases the risk of hepatic veno-occlusive disease, Blood, 100, 415a (abstr. 1611), 2002.
186. Stadtmauer, E. et al., Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg®, CMA-676), Blood, 98, 124a (abstr. 520), 2001.
187. Raza, A. et al., Preliminary analysis of a randomized phase 2 study of the efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg®) in patients with high risk myelodysplastic syndrome, Blood, 100, 795a (abstr. 3140), 2002.
188. Zwaan, Ch. M. et al., Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: First clinical experiences and relation with cellular sensitivity to single agent calicheamicin, Leukemia, 17, 468, 2003.
189. Leopold, L.H. et al., Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in the treatment of patients with acute myeloid leukemia in first relapse, Blood, 96, 504a, 2000.
190. Baccarani, M. et al., Preliminary report of a phase 2 study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg®) given in combination with cytarabine in patients with acute myeloid leukemia, Blood, 100, 341a (abstr. 1322), 2002
191. Estey, E.H. et al., Experience with gemtuzumab ozogamicin (“Mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia, Blood, 99, 4222, 2002.
192. Estey, E. et al., Mylotarg +/-IL-11 in patients age 65 and above with newly-diagnosed AML/MDS: Comparison with idarubicin + Ara-C, Blood, 98, 720a (abstr. 3007), 2001.
193. Estey, E.H. et al., Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: Comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside, Blood, 99, 4343, 2002.
194. Alvarez, R.H. et al., Pilot trial of Mylotarg, topotecan and Ara-C in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), Blood, 100, 340a (abstr. 1321), 2002.
195. Cortes, J. et al., Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia, Cancer Chemother. Pharmacol., 50, 497, 2002.
196. Raj, K. et al., Gemtuzumab ozogamicin is not associated with an increased risk of veno-occlusive disease in relapsed or refractory AML when used alone or in combination with flag chemotherapy, Br. J. Haematol., 117 (Suppl. 1), 20, 2002.
197. Giles, F. et al., Fatal hepatic veno-occlusive disease in a phase I study of Mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome, Acta Haematol. (Basel), 108, 164, 2002.
198. Kell, J.W. et al., Mylotarg (gemtuzumab ozogamicin: GO) given simultaneously with intensive and/or consolidation therapy for AML is feasible and may improve the response rate, Blood, 100, 199a (abstr. 746), 2002.
199. Venugopal, P. et al., Phase II study of gemtuzumab ozogamicin (Mylotarg) combined with intensive induction chemotherapy using high dose Ara-C and mitoxantrone followed by amifostine in poor prognosis acute myeloid leukemia: Preliminary results, Blood, 100, 341a (abstr. 1323), 2002.
200. Amadori, S. et al., Sequential administration of gemtuzumab ozogamicin (GO) and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: Interim results of the EORTC leukemia group AML-15A phase II trial, Blood, 98, 587a (abstr. 2465), 2001.
201. Sallah, A.S. et al., Combination imatinib and gemtuzumab ozogamicin in patients with chronic myeloid leukemia in myeloid blast crisis, Blood, 100, 319b (abstr. 4824), 2002.
202. Tsimberidou, A.M. et al., Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia (AML), Blood, 100, 339a (abstr. 1317), 2002.
203. Haran, V., Hiemenz, J., and Ballester, O.F., A phase I-II study of intensified induction and consolidation therapy with gemtuzumab ozogamicin for patients with high-risk acute myeloid leukemia: The AIM protocol, Blood, 100, 269b (abstr. 4608), 2002.
204. Alvarado, Y. et al., Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia, Cancer Chemother. Pharmacol., 51, 87, 2003.
205. Apostolidou, E. et al., Mylotarg, liposomal daunorubicin, Ara-C and cyclosporine (MDAC) regimen in patients with relapsed/refractory acute myelogenous leukemia (AML), Blood, 100, 268b (abstr. 4600), 2002.
206. Tanaka, M. et al., Prophylactic intravesical instillation of BCG in recurrent superficial bladder cancer: Is BCG treatment superior to other chemotherapeutic agents? J. Urol., 151, Suppl., 1994.
207. Takeshita, T., Salvage combination chemotherapy with enocitabine, aclarubicin and neocarzinostatin for recurrent or refractory acute myelogenous leukemia, Med. J. Kagoshima Univ., 52, 33, 2000.
208. Takahashi, T. et al., Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinoma, Cancer, 61, 881, 1988.
209. Otsuji, E. et al., Effects of idiotypic human anti-mouse antibody against in vitro binding and antitumor activity of a monoclonal antibody-drug conjugate, Hepato-Gastroenterology, 50, 380, 2003.
210. Fang, J., Sawa, T., and Maeda, H., Factors and mechanism of “EPR” effect and the enhanced antitumor effects of macromolecular drugs including SMANCS, Adv. Exp. Med. Biol., 519, 29, 2003.
211. Maeda, H., Sawa, T., and Konno, T., Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS, J. Controlled Release, 74, 47, 2001.
212. Maeda, H., SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy, Adv. Drug Delivery Rev., 46, 169, 2001.
213. Greish, K. et al., Macromolecular therapeutics: Advantages and prospects with special emphasis on solid tumor targeting, Clin. Pharmacokinetics, 42, 1089, 2003.
214. Tokura, S. et al., Induction of drug-specific antibody and the controlled release of drug by 6-Ocarboxymethyl-chitin, J. Controlled Release, 28, 235, 1994.
215. Nishikawa, T. et al., Cytological study on the effect of neocarzinostatin on sarcoma 180 in vivo, J. Antibiot., 18, 223, 1965.
216. Napier, M.A. et al., Neocarzinostatin: Spectral characterization and separation of a non-protein chromophore, Biochem. Biophys. Res. Commun., 89, 635, 1979.
217. Konishi, M. et al., Esperamicins, a novel class of potent antitumor antibiotics. I. Physico-chemical data and partial structure, J. Antibiot., 38, 1605, 1985.